Literature DB >> 25330743

Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.

Imit Kaur1, Ken M Kosak, Moises Terrazas, James N Herron, Steven E Kern, Kenneth M Boucher, Paul J Shami.   

Abstract

PURPOSE: O(2)-(2,4-dinitrophenyl)1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] or JS-K is a nitric oxide-producing prodrug of the arylated diazeniumdiolate class with promising anti-tumor activity. JS-K has challenging solubility and stability properties. We aimed to characterize and compare Pluronic(®) P123-formulated JS-K (P123/JS-K) with free JS-K.
METHODS: We determined micelle size, shape, and critical micelle concentration of Pluronic(®) P123. Efficacy was evaluated in vitro using HL-60 and U937 cells and in vivo in a xenograft in NOD/SCID IL2Rγ (null) mice using HL-60 cells. We compared JS-K and P123/JS-K stability in different media. We also compared plasma protein binding of JS-K and P123/JS-K. We determined the binding and Stern Volmer constants, and thermodynamic parameters.
RESULTS: Spherical P123/JS-K micelles were smaller than blank P123. P123/JS-K formulation was more stable in buffered saline, whole blood, plasma and RPMI media as compared to free JS-K. P123 affected the protein binding properties of JS-K. In vitro it was as efficacious as JS-K alone when tested in HL-60 and U937 cells and in vivo greater tumor regression was observed for P123/JS-K treated NOD/SCID IL2Rγ (null) mice when compared to free JS-K-treated NOD/SCID IL2Rγ (null) mice.
CONCLUSIONS: Pluronic(®) P123 solubilizes, stabilizes and affects the protein binding characteristics of JS-K. P123/JS-K showed more in vivo anti-tumor activity than free JS-K.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25330743      PMCID: PMC4359075          DOI: 10.1007/s11095-014-1542-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  30 in total

Review 1.  Glutathione metabolism and its implications for health.

Authors:  Guoyao Wu; Yun-Zhong Fang; Sheng Yang; Joanne R Lupton; Nancy D Turner
Journal:  J Nutr       Date:  2004-03       Impact factor: 4.798

Review 2.  The role of the protein-binding on the mode of drug action as well the interactions with other drugs.

Authors:  Christine Tesseromatis; Anastasia Alevizou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

3.  Nitric oxide: a cytotoxic activated macrophage effector molecule.

Authors:  J B Hibbs; R R Taintor; Z Vavrin; E M Rachlin
Journal:  Biochem Biophys Res Commun       Date:  1988-11-30       Impact factor: 3.575

4.  Thermodynamics of protein association reactions: forces contributing to stability.

Authors:  P D Ross; S Subramanian
Journal:  Biochemistry       Date:  1981-05-26       Impact factor: 3.162

5.  JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.

Authors:  Paul J Shami; Joseph E Saavedra; Lai Y Wang; Challice L Bonifant; Bhalchandra A Diwan; Shivendra V Singh; Yijun Gu; Stephen D Fox; Gregory S Buzard; Michael L Citro; David J Waterhouse; Keith M Davies; Xinhua Ji; Larry K Keefer
Journal:  Mol Cancer Ther       Date:  2003-04       Impact factor: 6.261

6.  Schedule and concentration-dependent induction of apoptosis in leukemia cells by nitric oxide.

Authors:  P J Shami; D L Sauls; J B Weinberg
Journal:  Leukemia       Date:  1998-09       Impact factor: 11.528

Review 7.  Nitric-oxide releasing molecules: a new class of drugs with several major indications.

Authors:  J L Burgaud; J P Riffaud; P Del Soldato
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

8.  Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization.

Authors:  Zhang Wei; Junguo Hao; Shi Yuan; Yajuan Li; Wu Juan; Xianyi Sha; Xiaoling Fang
Journal:  Int J Pharm       Date:  2009-05-03       Impact factor: 5.875

Review 9.  Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis.

Authors:  Lissbeth Leon; Jean-François Jeannin; Ali Bettaieb
Journal:  Nitric Oxide       Date:  2008-04-24       Impact factor: 4.427

10.  TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.

Authors:  Ann-Marie Simeone; Vanity McMurtry; René Nieves-Alicea; Joseph E Saavedra; Larry K Keefer; Marcella M Johnson; Ana M Tari
Journal:  Breast Cancer Res       Date:  2008-05-12       Impact factor: 6.466

View more
  2 in total

Review 1.  Glutathione S-transferase π: a potential role in antitumor therapy.

Authors:  Shu-Chen Dong; Huan-Huan Sha; Xiao-Yue Xu; Tian-Mu Hu; Rui Lou; Huizi Li; Jian-Zhong Wu; Chen Dan; Jifeng Feng
Journal:  Drug Des Devel Ther       Date:  2018-10-23       Impact factor: 4.162

2.  JS-K induces reactive oxygen species-dependent anti-cancer effects by targeting mitochondria respiratory chain complexes in gastric cancer.

Authors:  Xudong Zhao; Aizhen Cai; Zheng Peng; Wenquan Liang; Hongqing Xi; Peiyu Li; Guozhu Chen; Jiyun Yu; Lin Chen
Journal:  J Cell Mol Med       Date:  2019-01-22       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.